VXRT Vaxart

Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19

Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Europe 2023 in Barcelona, Spain on Wednesday, October 18 and Thursday, October 19, 2023.

Presentation Information:

Title: Transmission blocking strategies via oral tablet vaccination and mucosal immune induction

Speaker: Dr. Sean Tucker

Date: Wednesday, October 18, 2023

Time: 2:30 p.m. CET / 8:30 a.m. ET

Title: Protection against infection from an oral tablet norovirus candidate in humans

Speaker: Dr. James F. Cummings

Date: Thursday, October 19, 2023

Time: 11:00 a.m. CET / 5:00 a.m. ET

 

About Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts              

Vaxart Media Relations: Investor Relations:     
Mark Herr   Andrew Blazier
Vaxart, Inc.   FINN Partners
(203) 517-8957    (646) 871-8486   


EN
11/10/2023

Underlying

VXRTVaxart

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vaxart

 PRESS RELEASE
Free
VXRT VAXART

Vaxart Provides Business Update and Reports First Quarter 2025 Financi...

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company’s second-generation oral norovirus vaccine constructs, with topline data expected in mid-2025 New avian influenza vaccine candidate was 100% protective in a ferret challenge model, compared with 0% survival in placebo-treated animals Jeroen Grasman appointed as Chief Financial Officer effective May 19, 2025 Cash...

23h / 56m 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Appoints Jeroen Grasman as Chief Financial Officer

Vaxart Appoints Jeroen Grasman as Chief Financial Officer - Mr. Grasman brings over two decades of biotech financial leadership experience - SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the appointment of Jeroen Grasman as its Chief Financial Officer (CFO), effective May 19, 2025. Mr. Grasman succeeds Phillip Lee, who is resigning from his position as CFO for personal reasons. To ensure a smooth transition, Mr. Lee will remain with the Company as a non-executive employee through June 1, 2025. “We are delighted to welcome Jeroe...

May 13, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Pro...

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today addresses frequently asked stockholder questions regarding a reverse stock split proposal at the Company’s Annual Meeting taking place on Wednesday, May 21, 2025, to regain Nasdaq compliance. 1)   Why is Vaxart proposing a reverse stock split? a.   Vaxart is at risk of...

May 12, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting as Recommended by Leading Independent Proxy Advisory Firms SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today issued the following letter to its stockholders from its President & Chief Executive Officer, Steven Lo. Dear Vaxart, Inc. Stockholders: We are writing to update you on recent developments that positively impact Vaxart’s ability to advance our promising vaccine candidates and hi...

May 5, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Host First Quarter 2025 Business Update and Financial Result...

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13 Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webc...

May 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch